GUNN & Co INVESTMENT MANAGEMENT INC. Takes $363,000 Position in Bristol-Myers Squibb (NYSE:BMY)

GUNN & Co INVESTMENT MANAGEMENT INC. acquired a new position in shares of Bristol-Myers Squibb (NYSE:BMY) in the 4th quarter, HoldingsChannel.com reports. The firm acquired 7,069 shares of the biopharmaceutical company’s stock, valued at approximately $363,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of BMY. Lindbrook Capital LLC boosted its stake in Bristol-Myers Squibb by 2.3% in the 3rd quarter. Lindbrook Capital LLC now owns 8,060 shares of the biopharmaceutical company’s stock worth $468,000 after purchasing an additional 182 shares in the last quarter. BluePath Capital Management LLC purchased a new stake in shares of Bristol-Myers Squibb during the third quarter valued at $52,000. Brighton Jones LLC increased its position in shares of Bristol-Myers Squibb by 3.0% in the 3rd quarter. Brighton Jones LLC now owns 25,874 shares of the biopharmaceutical company’s stock valued at $1,502,000 after acquiring an additional 749 shares during the period. FORVIS Wealth Advisors LLC raised its stake in Bristol-Myers Squibb by 9.5% in the 3rd quarter. FORVIS Wealth Advisors LLC now owns 28,257 shares of the biopharmaceutical company’s stock worth $1,640,000 after acquiring an additional 2,446 shares during the last quarter. Finally, Keeler THomas Management LLC lifted its position in Bristol-Myers Squibb by 7.3% during the 3rd quarter. Keeler THomas Management LLC now owns 69,426 shares of the biopharmaceutical company’s stock worth $4,048,000 after acquiring an additional 4,740 shares during the period. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Wall Street Analyst Weigh In

BMY has been the topic of a number of research reports. Wells Fargo & Company increased their price objective on Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a report on Thursday, April 18th. StockNews.com lowered shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research report on Monday, April 15th. BMO Capital Markets reduced their target price on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating for the company in a report on Friday, April 26th. William Blair restated a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Monday, April 1st. Finally, Redburn Atlantic downgraded Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and cut their price target for the stock from $77.00 to $54.00 in a research report on Tuesday, February 6th. One research analyst has rated the stock with a sell rating, fifteen have given a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, Bristol-Myers Squibb currently has an average rating of “Hold” and an average price target of $60.00.

Bristol-Myers Squibb Stock Up 0.7 %

BMY stock opened at $43.99 on Monday. Bristol-Myers Squibb has a 52 week low of $43.33 and a 52 week high of $69.10. The firm has a 50-day simple moving average of $50.37 and a 200-day simple moving average of $50.65. The company has a quick ratio of 0.99, a current ratio of 1.11 and a debt-to-equity ratio of 2.99. The stock has a market capitalization of $89.17 billion, a P/E ratio of -14.19, a P/E/G ratio of 14.82 and a beta of 0.45.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($4.53) by $0.13. Bristol-Myers Squibb had a positive return on equity of 8.83% and a negative net margin of 13.50%. The firm had revenue of $11.87 billion for the quarter, compared to analyst estimates of $11.45 billion. During the same period in the previous year, the company posted $2.05 earnings per share. The business’s revenue was up 4.7% on a year-over-year basis. Equities analysts forecast that Bristol-Myers Squibb will post 0.59 earnings per share for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, May 1st. Stockholders of record on Friday, April 5th were given a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a dividend yield of 5.46%. The ex-dividend date of this dividend was Thursday, April 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is -77.42%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.